흡수성 혈관 스캐폴드 시장 : 소재별, 적응증별, 약제 용출형별, 스캐폴드 길이별, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Resorbable Vascular Scaffold Market is projected to grow by USD 779.98 million at a CAGR of 7.68% by 2032.

Resorbable vascular scaffolds (RVS) represent a next-generation coronary intervention platform designed to provide temporary vessel support and drug delivery, then gradually resorb to help restore vasomotion, reduce permanent metallic caging, and preserve future treatment options. The resorbable vascular scaffold market remains shaped by lessons from first-generation bioresorbable vascular scaffold programs, including the FDA-approved Absorb GT1 BVS, which was later withdrawn from commercial sale after clinical and adoption challenges, including concerns identified in comparative clinical follow-up.

Current opportunity is concentrated in improved scaffold architecture, thinner struts, magnesium and polymer platforms, optimized implantation protocols, and better patient and lesion selection. For manufacturers, the competitive path is no longer based on novelty alone; it depends on demonstrating clinical noninferiority or superiority versus contemporary drug-eluting stents, durable safety, predictable resorption, and procedural efficiency in real-world catheterization labs.

Transformative Shifts Reshaping RVS Innovation

The resorbable vascular scaffold landscape is shifting from first-generation enthusiasm to evidence-led product discipline. Earlier polymeric scaffolds showed the clinical importance of strut thickness, radial strength, expansion limits, and implantation technique. As a result, next-generation development is prioritizing thinner profiles, improved deliverability, shorter and more predictable resorption timelines, and more consistent vessel healing.

Regulatory expectations have also transformed. The U.S. FDA, European regulators under the Medical Device Regulation, and major Asian agencies increasingly require robust randomized data, long-term follow-up, and post-market surveillance. This favors organizations with strong clinical operations, material science expertise, imaging-guided procedure support, and physician education models that reduce scaffold thrombosis risk through correct sizing, lesion preparation, and high-pressure post-dilatation.

Cumulative Impact of Artificial Intelligence on RVS

Artificial intelligence is cumulatively improving the RVS value chain by strengthening design, trial execution, and clinical decision support. In R&D, AI-enabled simulation can evaluate scaffold geometry, radial force, degradation behavior, and vessel interaction before costly prototyping. Machine learning applied to intravascular imaging may also support more precise vessel sizing, calcium assessment, plaque characterization, and lesion selection.

In clinical development, AI can improve site selection, patient stratification, adverse-event signal detection, and real-world evidence generation. Its most immediate commercial impact is likely to be procedural optimization: integrating angiography, OCT, IVUS, and electronic health record data to identify patients most likely to benefit from temporary scaffolding while reducing inappropriate use in complex lesions where metallic drug-eluting stents remain better validated.

Key Regional Insights for RVS Adoption

Asia-Pacific is becoming an important RVS development and adoption arena because China, Japan, India, South Korea, and Australia combine high cardiovascular disease burden with expanding interventional cardiology capacity. Japan and South Korea emphasize rigorous clinical evidence, precision manufacturing, and quality systems, while China and India offer large procedural volumes, improving hospital infrastructure, and growing domestic medtech innovation. Australia contributes a registry-oriented and evidence-based adoption environment that supports careful evaluation of new coronary scaffold technologies.

North America remains evidence-driven, with the United States and Canada requiring strong safety data after the first-generation bioresorbable vascular scaffold experience. Europe continues to influence clinical standards through high-volume research centers and interventional cardiology networks, although Medical Device Regulation requirements have raised evidence, documentation, and compliance thresholds. Latin America, led by Brazil and Mexico, presents selective opportunities where adoption will depend on pricing discipline, reimbursement clarity, and training access. The Middle East, particularly advanced tertiary systems in Gulf countries, shows potential for premium cardiovascular technologies where specialist infrastructure is available, while Africa remains a longer-term opportunity constrained by uneven cath lab access, affordability, and advanced imaging availability.

Key Group Insights Across Strategic Market Blocs

ASEAN markets are attractive for future RVS expansion because urban cardiac centers in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are upgrading cath lab capabilities, but reimbursement and training variability require staged commercialization and physician education. The GCC is characterized by high cardiovascular risk factors, advanced tertiary hospitals, and strong demand for premium cardiovascular technologies, particularly where government-funded care and specialist referral systems support adoption of advanced interventional cardiology devices.

The European Union remains central for clinical evidence generation, harmonized regulatory scrutiny, and post-market vigilance, but Medical Device Regulation compliance increases documentation, clinical evaluation, and surveillance obligations. BRICS countries offer procedural scale, local manufacturing potential, and diverse access models, with China and India especially relevant for domestic device development and clinical volume. G7 markets set expectations for long-term safety, reimbursement evidence, registry transparency, and physician consensus. NATO membership is not a market driver by itself, but many NATO countries overlap with advanced procurement, regulatory, and hospital systems relevant to cardiovascular devices.

Key Country Insights in Resorbable Scaffold Markets

The United States is the most influential RVS market for regulatory credibility, but adoption depends on clear long-term safety and comparative outcomes versus leading drug-eluting stents, supported by rigorous clinical follow-up and real-world evidence. Canada follows evidence-based procurement and reimbursement scrutiny, while Mexico and Brazil offer regional volume potential if pricing, imaging access, and operator training barriers are addressed. The United Kingdom, Germany, France, Italy, and Spain remain important European clinical hubs, with Germany particularly relevant for interventional cardiology innovation, hospital-based evaluation, and early specialist engagement.

Russia presents a more complex access environment shaped by sanctions, localization requirements, supply chain restrictions, and procurement constraints. China and India offer large patient populations, expanding interventional cardiology capacity, and active domestic device ecosystems, making them central to future RVS development and adoption strategies. Japan and South Korea demand high-quality evidence, precision manufacturing, and strong regulatory documentation, while Japan's aging population and South Korea's advanced hospital systems support focused evaluation of coronary innovation. Australia is a sophisticated but smaller market where reimbursement, specialist endorsement, clinical registries, and outcomes transparency strongly influence uptake.

Actionable Recommendations for RVS Industry Leaders

Industry leaders should prioritize clinically meaningful differentiation rather than broad claims of bioresorption. Development programs need predefined imaging endpoints, adequately powered randomized trials, and long-term follow-up focused on scaffold thrombosis, target lesion failure, late lumen loss, vessel healing, and restoration of vasomotion. Evidence should be benchmarked against current-generation drug-eluting stents, not against older platforms.

Commercial teams should build adoption around training-certified implantation protocols, including lesion preparation, accurate sizing, and post-dilatation. Integration with OCT and IVUS workflows can improve procedural consistency and support appropriate patient selection. Organizations should also design market access strategies early, combining health economics, registry data, and real-world evidence to demonstrate where temporary scaffolding creates value for patients, clinicians, and payers.

Research Methodology for RVS Market Analysis

This executive summary is based on a structured secondary research approach using publicly available regulatory records, peer-reviewed clinical literature, clinical trial publications, medical society discussions, product documentation, and market intelligence on interventional cardiology technologies. Emphasis is placed on verified developments such as first-generation scaffold clinical outcomes, regulatory approval pathways, commercial withdrawals, evolving device evaluation standards, and advances in coronary imaging-guided intervention.

The methodology prioritizes triangulation across clinical trials, registries, product documentation, regulatory communications, and regional healthcare infrastructure indicators. Insights are interpreted through the lens of device safety, procedural adoption, reimbursement feasibility, clinical workflow integration, and competitive positioning versus contemporary drug-eluting stents. No unverified market-size figures are used; conclusions focus on evidence-backed directional trends and strategic implications.

Conclusion: Evidence Will Define the RVS Future

The resorbable vascular scaffold market is entering a more mature phase defined by scientific rigor, selective adoption, and next-generation engineering. The category's long-term potential remains compelling because temporary vascular support addresses an unmet clinical aspiration: treating coronary lesions without leaving a permanent implant behind.

However, the path to sustainable growth requires proof. Manufacturers must demonstrate safer scaffold design, predictable degradation, procedural reproducibility, and patient-specific value. Markets with strong clinical governance, intravascular imaging capability, trained operators, and reimbursement sophistication will likely lead early adoption, while broader global expansion will depend on cost-effectiveness, supply reliability, and training. The winners will be organizations that translate bioresorption from an appealing concept into consistently validated cardiovascular outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Resorbable Vascular Scaffold Market, by Material Type

• 7.1. Polymer-based
  • 7.1.1. Poly-L-lactic Acid (PLLA)
  • 7.1.2. Poly-glycolic Acid (PGA)
  • 7.1.3. Polycaprolactone (PCL)
  • 7.1.4. Poly-dioxanone (PDO)
• 7.2. Metal-based
  • 7.2.1. Magnesium Alloys
  • 7.2.2. Iron-based Alloys
  • 7.2.3. Zinc-based Alloys

8. Resorbable Vascular Scaffold Market, by Indication Type

• 8.1. Coronary Artery Disease
• 8.2. Peripheral Arterial Disease
  • 8.2.1. Femoral Artery Disease
  • 8.2.2. Popliteal Artery Disease
  • 8.2.3. Tibial Artery Disease

9. Resorbable Vascular Scaffold Market, by Drug Elution Type

• 9.1. Drug Eluting Scaffolds
  • 9.1.1. Sirolimus Eluting
  • 9.1.2. Everolimus Eluting
  • 9.1.3. Paclitaxel Eluting
  • 9.1.4. Biolimus Eluting
• 9.2. Non Drug Eluting Scaffolds

10. Resorbable Vascular Scaffold Market, by Scaffold Length

• 10.1. 18 To 28 Millimeter
• 10.2. Greater Than 28 Millimeter
• 10.3. Less Than 18 Millimeter

11. Resorbable Vascular Scaffold Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Cardiac Centers
• 11.3. Hospitals

12. Resorbable Vascular Scaffold Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Resorbable Vascular Scaffold Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Resorbable Vascular Scaffold Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Balton Sp. z o.o.
• 16.3. Biotronik SE & Co. KG
• 16.4. Boston Scientific Corporation
• 16.5. Cook Medical LLC
• 16.6. Elixir Medical Corporation
• 16.7. Kyoto Medical Planning Co., Ltd.
• 16.8. Lepu Medical Technology (Beijing) Co., Ltd.
• 16.9. Lifetech Scientific Corporation
• 16.10. Meril Life Sciences Pvt. Ltd.
• 16.11. MicroPort Scientific Corporation
• 16.12. OrbusNeich Medical Company Limited
• 16.13. REVA Medical LLC
• 16.14. Sahajanand Medical Technologies Pvt. Ltd.
• 16.15. Terumo Corporation
• 16.16. Translumina Therapeutics LLP
• 16.17. Zorion Medical Inc.